These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 18479500)

  • 1. Vitiligo and melanoma-associated hypopigmentation (MAH): shared and discriminative features.
    Hartmann A; Bedenk C; Keikavoussi P; Becker JC; Hamm H; Bröcker EB
    J Dtsch Dermatol Ges; 2008 Dec; 6(12):1053-9. PubMed ID: 18479500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melanoma-associated leukoderma and vitiligo cannot be differentiated based on blinded assessment by experts in the field.
    Lommerts JE; Teulings HE; Ezzedine K; van Geel N; Hartmann A; Speeckaert R; Spuls PI; Wolkerstorfer A; Luiten RM; Bekkenk MW
    J Am Acad Dermatol; 2016 Dec; 75(6):1198-1204. PubMed ID: 27717621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanoma-associated hypopigmentation: where are the antibodies?
    Merimsky O; Shoenfeld Y; Baharav E; Altomonte M; Chaitchik S; Maio M; Ferrone S; Fishman P
    Am J Clin Oncol; 1996 Dec; 19(6):613-8. PubMed ID: 8931683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypopigmented mycosis fungoides: a clinical mimicker of vitiligo.
    Tolkachjov SN; Comfere NI
    J Drugs Dermatol; 2015 Feb; 14(2):193-4. PubMed ID: 25689815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Segmental vitiligo-like hypopigmentation associated with metastatic melanoma.
    Cerci FB; Mesquita LA; Silva de Castro CC
    Cutis; 2017 Jun; 99(6):E1-E2. PubMed ID: 28686764
    [No Abstract]   [Full Text] [Related]  

  • 6. Origin, clinical presentation, and diagnosis of hypomelanotic skin disorders.
    Mollet I; Ongenae K; Naeyaert JM
    Dermatol Clin; 2007 Jul; 25(3):363-71, ix. PubMed ID: 17662902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor of follicular infundibulum: an unsuspected cause of macular hypopigmentation.
    Kubba A; Batrani M; Taneja A; Jain V
    Indian J Dermatol Venereol Leprol; 2014; 80(2):141-4. PubMed ID: 24685851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological basis of melanoma-associated vitiligo-like depigmentation.
    González R; Torres-López E
    Actas Dermosifiliogr; 2014 Mar; 105(2):122-7. PubMed ID: 23146137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Double Strike Hypothesis of the vitiligo pathomechanism: new approaches to vitiligo and melanoma.
    Michelsen D
    Med Hypotheses; 2010 Jan; 74(1):67-70. PubMed ID: 19748188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The significance of eccentric and central hyperpigmentation, multifocal hyper/hypopigmentation, and the multicomponent pattern in melanocytic lesions lacking specific dermoscopic features of melanoma.
    Arevalo A; Altamura D; Avramidis M; Blum A; Menzies S
    Arch Dermatol; 2008 Nov; 144(11):1440-4. PubMed ID: 19015418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo).
    Merimsky O; Shoenfeld Y; Baharav E; Zigelman R; Fishman P
    Hum Antibodies Hybridomas; 1996; 7(4):151-6. PubMed ID: 9140726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitiligo-like primary melanoma.
    Lugo-Somolinos A; Sánchez JL; Garcia ME
    Am J Dermatopathol; 2008 Oct; 30(5):451-4. PubMed ID: 18806487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DeRmpath & Clinic: Regressive melanoma associated with vitiligo-like depigmentation.
    Gouillon L; Villani AP; Kanitakis J
    Eur J Dermatol; 2016 Aug; 26(4):420-1. PubMed ID: 27528475
    [No Abstract]   [Full Text] [Related]  

  • 14. Application of a pigment measuring device--Mexameter--for the differential diagnosis of vitiligo and nevus depigmentosus.
    Park ES; Na JI; Kim SO; Huh CH; Youn SW; Park KC
    Skin Res Technol; 2006 Nov; 12(4):298-302. PubMed ID: 17026663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perilesional vitiligo in melanoma.
    Pantoja E; Wendth AJ; Beecher TS
    Cutis; 1977 Jan; 19(1):51-3. PubMed ID: 837717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Juvenile-onset hypopigmented mycosis fungoides mimicking vitiligo.
    Ngo JT; Trotter MJ; Haber RM
    J Cutan Med Surg; 2009; 13(4):230-3. PubMed ID: 19706233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presentations, Signs of Activity, and Differential Diagnosis of Vitiligo.
    Goh BK; Pandya AG
    Dermatol Clin; 2017 Apr; 35(2):135-144. PubMed ID: 28317523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study.
    Quaglino P; Marenco F; Osella-Abate S; Cappello N; Ortoncelli M; Salomone B; Fierro MT; Savoia P; Bernengo MG
    Ann Oncol; 2010 Feb; 21(2):409-414. PubMed ID: 19622589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated Levels of SOX10 in Serum from Vitiligo and Melanoma Patients, Analyzed by Proximity Ligation Assay.
    Blokzijl A; Chen LE; Gustafsdottir SM; Vuu J; Ullenhag G; Kämpe O; Landegren U; Kamali-Moghaddam M; Hedstrand H
    PLoS One; 2016; 11(4):e0154214. PubMed ID: 27110718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical significance of antityrosinase antibodies in melanoma and related hypopigmentary lesions.
    Merimsky O; Shoenfeld Y; Fishman P
    Clin Rev Allergy Immunol; 1998; 16(3):227-36. PubMed ID: 9773250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.